The release of NETs facilitated by the lytic activity of GSDMD in neutrophils may represent a pivotal event in ARDS development.[145] Consequently, blocking the GSDMD‐mediated release of NETs mediated by GSDMD might offer a promising mechanism for treating associated inflammatory diseases. This evidence concerns the gene GSDMD and acute respiratory distress syndrome.